Gliomas Clinical Trial
Official title:
Diffusion Kurtosis Imaging en MR Spectroscopy in Grading and the Characterization of Tumour Infiltration in Gliomas
In this study, we evaluate the role of diffusion kurtosis imaging (DKI) and MR spectroscopy
(MRS), two advanced imaging techniques in magnetic resonance (MR) in grading and detection
of microscopic infiltrating tumour in gliomas. These parameters are of utmost importance in
optimal choice and planning of treatment.
Patients treated with gliomatous brain tumours are included voluntarily. They undergo one
imaging session on a 3T MR scanner prior to treatment.
DKI data are quantitively analyzed in order to estimate specific parameters in normal
appearing white matter, grey matter, tumor and peritumoral edema. MRS data are analyzed
quantitatively and qualitatively with peak integration, ratio calculation and classification
algorithms. Histological confirmation is obtained at subsequent surgery.
Information from this study can be of significant importance in avoiding brain biopsies.
Furthermore, information on microscopic tumour spread can be used during neurosurgery or in
radiotherapy planning. An important advantage of these advanced MR techniques is the
non-invasivity and the lack of ionizing radiation, two important issues in this relatively
young patient population.
n/a
Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT03952598 -
Studying the Biology of IDH-mutant Gliomas Via Longitudinal Observation of 2-hydroxyglutarate (2-HG) Using MR Spectroscopy
|
N/A | |
| Not yet recruiting |
NCT01445691 -
More Complete Removal of Malignant Brain Tumors by Fluorescence-Guided Surgery
|
Phase 2 | |
| Terminated |
NCT01251913 -
A Pilot Study of Inpatient Hospice With Procurement of Brain Tumor Tissue on Expiration for Research Purposes
|
||
| Withdrawn |
NCT01961934 -
C11-Sodium Acetate PET/CT Imaging Evaluation in Brain Glioma, Post Therapy Necrosis and Pseudo-progression
|
Phase 2/Phase 3 | |
| Active, not recruiting |
NCT03557359 -
Nivolumab for Recurrent or Progressive IDH Mutant Gliomas
|
Phase 2 | |
| Recruiting |
NCT01655927 -
Efficacy of Tranexamic Acid in Brain Tumor Resections
|
Phase 3 | |
| Completed |
NCT01144247 -
Cellular Immunotherapy Study for Brain Cancer
|
Phase 1 | |
| Completed |
NCT00967577 -
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
|
Phase 1 | |
| Terminated |
NCT01517776 -
Cilengitide and Metronomic Temozolomide for Relapsed or Refractory High Grade Gliomas or Diffuse Intrinsic Pontine Gliomas in Children and Adolescents
|
Phase 2 | |
| Completed |
NCT00832598 -
[18F] FACBC and [18F] FLT PET Imaging in Central Nervous System Tumors
|
N/A | |
| Completed |
NCT00589706 -
A Phase II Study of Adjuvant Use of Anti-Epidermal Growth Factor Receptor EGFR-425 in High Grade Gliomas
|
Phase 2 | |
| Completed |
NCT03154996 -
Chronic Convection Enhanced Delivery of Topotecan
|
Phase 1 | |
| Withdrawn |
NCT05054400 -
Study of Laser Interstitial Thermal Therapy (LITT) Treatment Response Assessment With Fluciclovine PET MR
|
Early Phase 1 | |
| Recruiting |
NCT03091270 -
ZOOMit-fMRI Identifies Motor Functional Cortex
|
||
| Completed |
NCT00200161 -
Temozolomide & RT Followed by Dose Dense vs Temozolomide & Retinoic Acid in Pts w/Glioblastoma
|
Phase 2 | |
| Terminated |
NCT02332889 -
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05804227 -
Window-of-Opportunity Trial of Ulixertinib for MAPK-Activated Low-Grade Gliomas in Adults
|
Early Phase 1 |